Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 3, 2012, Pages 1433-1438

  Plantevin Krenitsky, Véronique ^a   Nadolny, Lisa ^a   Delgado, Mercedes ^a   Ayala, Leticia ^a   Clareen, Steven S ^a   Hilgraf, Robert ^a   Albers, Ronald ^a   Hegde, Sayee ^a   D'Sidocky, Neil ^a   Sapienza, John ^a   Wright, Jonathan ^a   McCarrick, Meg ^a   Bahmanyar, Sogole ^a   Chamberlain, Philip ^a   Delker, Silvia L ^a   Muir, Jeff ^a   Giegel, David ^a   Xu, Li ^a   Celeridad, Maria ^a   Lachowitzer, Jeff ^a   Bennett, Brydon ^a   Moghaddam, Mehran ^a   Khatsenko, Oleg ^a   Katz, Jason ^a   Fan, Rachel ^a   Bai, April ^a   Tang, Yang ^a   Shirley, Michael A ^a   Benish, Brent ^a   Bodine, Tracey ^a   Blease, Kate ^a   Raymon, Heather ^a   Cathers, Brian E ^a   Satoh, Yoshitaka ^a   more..

^a CELGENE CORPORATION   (United States)

Author keywords

Aminopurine based JNK inhibitors; CC 930; Idiopathic pulmonary fibrosis; Jun N terminal kinase; Structure based drug design

Indexed keywords

ANTIFIBROTIC AGENT; TANZISERTIB;

ARTICLE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME INHIBITION; LUNG FIBROSIS; MOLECULAR WEIGHT; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; CATALYTIC DOMAIN; CYCLOHEXANOLS; DOGS; ENZYME ACTIVATION; ENZYME INHIBITORS; HAPLORHINI; IDIOPATHIC PULMONARY FIBROSIS; INHIBITORY CONCENTRATION 50; MAP KINASE KINASE 4; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PURINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 84862776641     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.12.027     Document Type: Article

References (30)

1. H.-P. Hauber, and M. Blaukovitsch Inflamm. Allergy: Drug Targets 9 2010 158
2. R.H. Gomer, and M.L. Lupher Jr. Expert Opin. Invest. Drugs 19 2010 737
3. R.M. du Bois Nat. Rev. Drug Discov. 9 2010 129
4. G. Raghu, H.R. Collard, J.J. Egan, F.J. Martinez, J. Behr, K.K. Brown, T.V. Colby, J.-F. Cordier, K.R. Flaherty, J.A. Lasky, D.A. Lynch, J.H. Ryu, J.J. Swigris, A.U. Wells, J. Ancochea, D. Bouros, C. Carvalho, U. Costabel, M. Ebina, D.M. Hansell, T. Johkoh, D.S. Kim, T.E. King Jr., Y. Kondoh, F. Myers, N.L. Müller, A.G. Nicholson, L. Richeldi, M. Selman, R.F. Dudden, B.S. Griss, S.L. Protzko, and H.L. Schünemann Am. J. Respir. Crit. Care Med. 183 2011 788
5. Plantevin Krenitsky, V., Nadolny, L., Sahasrabudhe, K., Ayala, L., Delgado, M., Clareen, S., Hilgraf, R., Albers, R., Kois, A., Hughes, K., Wright, J., Sudbeck, E., Ghosh, S., Nowakowski, J., Muir, J., Cathers, B., Giegel, D., Xu, L., Celeridad, M., Moghaddam, M., Khatsenko, O., Omholt, P., Pai, S., Fan, R., Tang, Y., Shirley, M. A., Benis, B., Blease, K., Raymon, H., Bhagwat, S., Henderson, I., Cole, A. G., Bennett, B., Satoh, Y. Preceding article.
6. S. Tanemura, T. Yamasaki, T. Katada, and H. Nishina Curr. Enz. Inhib. 6 2010 26
7. P.R. Eynott, P. Nath, S.-Y. Leung, I.M. Adcock, B.L. Bennett, and K.F. Chung Br. J. Pharmacol. 140 2003 1373
8. M.H. de Borst, J. Prakash, M. Sandovici, P.A. Klok, I. Hamming, R.J. Kok, G. Navis, and H. van Goor J. Pharmacol. Exp. Ther. 331 2009 896
9. J. Kluwe, J.-P. Pradere, G.-Y. Gwak, A. Mencin, S. De Minicis, C.H. Osterreicher, J. Colmenero, R. Bataller, and R.F. Schwabe Gastroenterology 138 2010 347
10. W. Wu, A. Muchir, J. Shan, G. Bonne, and Howard J. Worman Circulation 123 2011 53
11. M.H. De Borst, J. Prakash, W.B.W.H. Melenhorst, M.C. van den Heuvel, R.J. Kok, G. Navis, and H. van Goor J. Pathol. 213 2007 219
12. M.A. Siddiqui, and P.A. Reddy J. Med. Chem. 53 2010 3005
13. ss (>7 L/kg). See also D.A. Smith, B.C. Jones, and D.K. Walker Med. Res. Rev. 16 1996 243
14. M.P. Gleeson J. Med. Chem. 51 2008 817
15. M. Morgenthaler, E. Schweizer, A. Hoffmann-Röder, F. Benini, R.E. Martin, G. Jaeschke, B. Wagner, H. Fischer, S. Bendels, D. Zimmerli, J. Schneider, F. Diederich, M. Kansy, and K. Müller ChemMedChem 2 2007 1100
16. Experimental details on biochemical and cellular assays can be found in the Supplementary data section.
17. N.H.P. Cnubben, J. Vervoort, M.G. Boersma, and Y.M.C.M. Rietjens Biochem. Pharmacol. 49 1995 1235
18. S.D. Nelson Curr. Ther. Res. 62 2001 885
19. A.S. Kalgutkar, I. Gardner, R.S. Obach, C.L. Shaffer, E. Callegari, K.R. Henne, A.E. Mutlib, D.K. Dalvie, J.S. Lee, Y. Nakai, J.P. O'Donnell, J. Boer, and S.P. Harriman Curr. Drug Met. 6 2005 161
20. This class of compounds is 8-10 times more potent in JNK2 and JNK3 than JNK1.
21. Model for the assessment of the potential anti-inflammatory effects of therapeutic agents on acute cytokine production by measuring the effect of a compound administered by oral gavage, on the release of plasma tumor necrosis factor (TNF)-α following lipopolysaccharide (LPS) injection. See Supplementary data for details.
22. The JNK3 isoform was the only one available to us for crystallography during this drug discovery program.
23. All images were generated using using The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC.
24. The PDB deposition code for 1 JNK3 complex crystal structure is 3TTI.
25. See Supplementary data for details.
26. N.M. Davies Reddy Mehvar Chiral Inversion Chirality and Drug Design and Development 2004 Marcel Dekker Inc. New York 351 392 Chapter 8
27. A similar trend was observed prior to the profiling of 1 with compounds containing cis-hydroxy cyclohexyl amine at the C2 position. See also: M.Y. Chu-Moyer, W.E. Ballinger, D.A. Beebe, J.B. Coutcher, W.W. Day, J. Li, P.J. Oates, and R.M. Weekly Bioorg. Med. Chem. Lett. 12 2002 1477
28. The percentage of the cis isomer was calculated in vivo based on the po AUC. The major isomerization in mouse and rat hepatocytes translated in the in vivo formation of 20% and 200%, respectively of the cis isomer. On the other hand, the isomerization in dog was below limit of detection in vitro and tracked with a 1.5% formation in vivo. Trace isomerization in monkey resulted in trace formation in vivo as well. A similar profile was observed with analogs containing a trans-hydroxy cyclohexyl amine at C2.
29. Y. Ye, L. Kong, M. Assaf, L. Liu, A. Wu, H. Lau, S. Choudhury, and O. Laskin Clin. Pharmacol. Ther. 89 2011 31
30. www.clinicaltrials.gov; Trial Identifier NCT01203943.